Table 1.
Demographics of the subjects in GERA, MGB Biobank and Rotterdam Study analysed for the oral corticosteroid burst outcome
| GERA (n=5710) |
MGB biobank (n=676) |
Rotterdam study (n=465) |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases (n=3097) | Controls (n=2613) | P value | Cases (n=229) | Controls (n=447) | P value | Cases (n=274) | Controls (n=191) | P value | |
| Age (years, mean±SD) | 63.8 (±14.0) | 63.4 (±15.2) | 0.24 | 57.7 (±15.4) | 59.9 (±15.9) | 0.09 | 63.7 (±8.7) | 62.5 (±9.0) | 0.16 |
|
| |||||||||
| Female sex | 2168 (70.0%) | 1765 (67.5%) | 0.046 | 160 (69.9%) | 274 (61.3%) | 0.03 | 191 (69.7%) | 132 (69.1%) | 0.97 |
|
| |||||||||
| Smoking status | <0.001 | 0.74 | 0.43 | ||||||
|
| |||||||||
| Never | 1622 (54.1%) | 1481 (59.1%) | 78 (59.1%) | 146 (60.8%) | 105 (38.3%) | 65 (34.0%) | |||
|
| |||||||||
| Current or Former | 1378 (45.9%) | 1027 (40.9%) | 54 (40.9%) | 94 (39.2%) | 168 (61.3%) | 124 (65.0%) | |||
|
| |||||||||
| BMI (kg/m2, mean±SD) | 29.2 (±6.2) | 28.6 (±6.3) | <0.05 | 30.6 (±7.7) | 29.0 (±7.6) | 0.06 | 28.1 (±4.4) | 28.2 (±4.9) | 0.9 |
|
| |||||||||
| Co-morbidities | |||||||||
|
| |||||||||
| Allergic rhinitis | 1404 (45.3%) | 1113 (42.6%) | <0.05 | 156 (68.1%) | 285 (63.8%) | 0.26 | – | – | – |
|
| |||||||||
| GERD* | 983 (31.7%) | 651 (24.9%) | <0.001 | 153 (66.8%) | 281 (62.9%) | 0.31 | – | – | – |
|
| |||||||||
| Concurrent asthma medications | |||||||||
|
| |||||||||
| Long-acting β-agonists | 333 (10.8%) | 117 (4.5%) | <0.001 | 158 (69.0%) | 181 (40.5%) | <0.001 | 239 (87.2%) | 125 (65.4%) | <0.001 |
|
| |||||||||
| Anti-leukotrienes | 149 (4.8%) | 71 (2.7%) | <0.001 | 87 (38.0%) | 77 (17.2%) | <0.001 | 56 (20.4%) | 15 (7.9%) | <0.001 |
|
| |||||||||
| Anti-cholinergics | 110 (3.6%) | 37 (1.4%) | <0.001 | 64 (27.9%) | 54 (12.1%) | <0.001 | 178 (65.0%) | 73 (38.2%) | <0.001 |
|
| |||||||||
| Biologics† | – | – | – | 6 (2.6%) | 0 (0.0%) | 0.001 | – | – | – |
*
Gastro-oesophageal reflux disease.
†
No subjects in GERA or Rotterdam Study on biologics. In MGB Biobank, omalizumab and mepolizumab only.
BMI, body mass index; GERA, Genetic Epidemiology Research on Adult and Aging; MGB, Mass General Brigham.